Stock search

Ticker or company name

Compare stocks

Market: US

  • GILDGilead Sciences

Add stock

Ticker or company

Summary

GILD
Gilead Sciences
$167,58Down −0,30%
Year: Up +34%
25/100Ratio would not consider buying
Open stock page

Verdict

GILD has 5 of 10 checks in the red zone.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckGILD1 ✓ 2 — 5 ✕
P/E vs its history—
P/E vs industry—
Forward P/En/a20,9
Revenue growth, YoY+6,5%
EPS growth, YoY—
Net margin−12,5%
Net debt / EBITDA—
Free cash flow$13,8 bn
Share count over a year−0,2%
Cash runwayn/anot needed

Metrics

Best WorstNo mark — in between

Metric · betterGILDTTMIndustry medianTTM
P/E TTM ↓n/a42,1
Forward P/E ↓20,918,7
PEG ↓n/a4,1
P/S TTM ↓6,76,6
EV/EBITDA ↓18,828,2
P/FCF ↓15,126,0

Price, %

  • GILDn/a

Returns

Best WorstNo mark — in between

PeriodGILD
1 yearn/a
3 yearsn/a
5 yearsn/a
All timen/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

GILD
Share of “buy”83%
Beat the forecast4 of 4
Average “surprise”+6,9%
Insiders over 12 monthssales $102 m

Details are on each stock page.